Friday 6 November 2026
Export EXEL’s income statement to Excel — free account
Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
69.55
0.84
+1.22%
Follow EXEL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 7 | 7 | 7 |
| 35.53% | 40.99% | 44.39% | 44.32% | ||
| 27.02% | 30.69% | 33.28% | 33.17% | ||
ROIC |
49.46% | 50.53% | 60.45% | 66.59% | |
Return on Tangible Assets |
68.85% | 89.31% | 87.68% | 88.78% | |
Average Days of Receivables |
45.14 | 50.54 | 48.28 | 48.02 | |
Free Cash Flow per Share |
3.11 | 3.50 | 4.62 | 4.64 | |
Free Cash Flow |
844.34 | 905.17 | 1,158.19 | 1,144.49 | |
Capital Expenditures |
(39.93) | (19.51) | (25.24) | (28.57) | |
| Other line items | |||||
Cash ROIC |
26.22% | 33.36% | 43.17% | 41.99% | |
Accounts Receivable Turnover |
8.40 | 7.78 | 7.93 | 7.82 | |
Accounts Payable Turnover |
2.47 | 2.52 | 2.64 | 3.32 | |
Inventory Turnover |
3.80 | 3.28 | 3.28 | 3.26 | |
Average Days of Payables |
129.19 | 104.36 | 166.43 | 120.59 | |
Days of Inventory on Hand |
94.57 | 114.95 | 122.41 | 116.83 | |
Tax Rate |
(0.17) | (0.17) | (0.17) | (0.17) | |
Research and Development Expense of Revenue |
35.56% | 34.21% | 33.84% | 33.43% | |
Selling, General and Administrative Expense of Revenue |
22.36% | 21.94% | 21.92% | 22.62% | |
Share Based Compensation of Revenue |
4.87% | 4.89% | 4.62% | 4.42% | |
Operating CF/Net income |
1.13 | 1.11 | 1.38 | 1.33 | |
Depreciation/Fixed assets |
0.29 | 0.30 | 0.31 | 0.32 | |
Capex/Depreciation |
(1.37) | (0.68) | (0.89) | (1.03) | |
Revenue per Share |
8.54 | 9.20 | 9.71 | 10.12 | |
Operating CF per Share |
3.26 | 3.58 | 4.72 | 4.75 | |
Capex per Share |
(0.15) | (0.08) | (0.10) | (0.12) | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026